Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL200293 | 0.82 | MAPK1 (0.40) | ELANEALDH1A1POLBKDM4EMAPK1 | |
| SCHEMBL13727061 | 0.81 | POLB (0.50) | ALDH1A1POLBKDM4EL3MBTL1NPC1 | |
| SCHEMBL15445468 | 0.79 | ELANE (0.47) | ELANEALDH1A1KDM4EMAPK1L3MBTL1 | |
| SCHEMBL11812944 | 0.78 | FFAR1 (0.44) | ALDH1A1POLBKDM4ENPC1MAPT | |
| SCHEMBL7557424 | 0.77 | NPC1 (0.41) | ELANEALDH1A1POLBKDM4ENPC1 | |
| SCHEMBL4043786 | 0.77 | GAA (0.53) | ALDH1A1POLBL3MBTL1 | |
| SCHEMBL28832050 | 0.77 | NPC1 (0.33) | ALDH1A1NPC1CES2CES1RAB9A | |
| SCHEMBL17607318 | 0.77 | NPC1 (0.40) | ELANEALDH1A1NPC1KMT2ALMNA | |
| Benzene SCHEMBL29290216 | 0.75 | ALDH1A1 (0.56) | ALDH1A1POLBKDM4ENPC1MAPT | |
| SCHEMBL688471 | 0.75 | ALDH1A1 (0.56) | ALDH1A1POLBKDM4ENPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | TRIM33, TRIM28, TRIM4 | ELANE 2834/4885ALDH1A1 3246/4885POLB 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.